Back to search

Article

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor

2023-08-16

Abstract excerpt

<h4>ABSTRACT</h4> The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores function of the pathogenic mutated CFTR channel. We performed a single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome, intestinal inflammation, and cli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ea0fdbb6-d2da-58a3-82fb-a25e64acc7be
DOI
10.1101/2023.08.11.23293949
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorDOI 10.1101/2023.08.11.23293949
Select a neighboring publication to make it the new centre.